Joseph A. Caprini, MD, MS, FACS, RVT
|
|
|
- Rodger Kelly
- 9 years ago
- Views:
Transcription
1 Joseph A. Caprini, MD, MS, FACS, RVT Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical Professor of Surgery University of Chicago Pritzker School of Medicine, Chicago, IL
2 Yellowstone Park
3 Pulmonary Embolism The patient presented to ER with nonproductive cough, mild wheezing, dyspnea, and moderate back pain for 5 days The patient developed a massive PE and died 3 days after admission to intensive care unit The patient did not receive prophylaxis! Photo courtesy of Victor F. Tapson, MD.
4 The Many Faces Of Venous Thromboembolism Prevent Fatal pulmonary emboli. 1-5% incidence in patients with >4 risk factors. 16.7% mortality at 3 months. 34% of those with Pulmonary emboli present as sudden death. Prevent chronic pulmonary hypertension 4% of patients suffering PE Prevent clinical venous thromboembolism. Morbidity, drugs, tests, hose, changes in life style Phlegmasia Cerula & alba Dolens Venous Gangrene with limb loss Prevent silent venous thromboembolism. Risk of subsequent event double that of control population. Prevent embolic stroke (20-30% PFO rate). 50% disabled; 20% die; 30% recover. Prevent the post thrombotic syndrome and venous insufficiencyinduced lymphedema. 25% incidence following DVT and 7% severe. May not be evident for 2-5 YEARS>
5 Risk Assessment I m sorry, the CAT scanner is broken, so I ll have to take your history and physical.
6 Thrombosis Risk Scoring Assign a point value to each risk factor according to the relative risk of VTE based on the literature. Total the points to obtain a score. Compare the scores to 30 & 60 day incidence of clinically relevant VTE. Use prophylaxis for a score of 4 or more Use extended prophylaxis for a score of >8. Caprini JA, Arcelus JI, Hasty JH, et al. Clinical assessment of venous thromboembolic risk in surgical patients. Seminars in Thrombosis & Hemostasis 1991;17 Suppl 3:
7 *V. Bahl, H. Hu, P. K. Henke, T. W. Wakefield, D. A. Campbell, J, Caprini JA. Ann Surg: 2010; 251: 344-5
8 A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Method *V. Bahl, H. Hu, P. K. Henke, T. W. Wakefield, D. A. Campbell, J, Caprini JA. Ann Surg: 2010; 251: Low Risk (n=76) Moderate Risk High Risk Highest Risk (868) (3,001) (3,012) (1,008) (261) Clinically evident-imaging proven VTE rates at 30 Days
9 A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Method *V. Bahl, H. Hu, P. K. Henke, T. W. Wakefield, D. A. Campbell, J, Caprini JA. Ann Surg: 2010; 251: 344-5
10 Validation of the Caprini Risk Assessment Model in Plastic and Reconstructive Surgery Patients Panucci,C. et al: J Am Coll Surg 2011;212:
11 Evidence-Based Practices for Thromboembolism Prevention: Summary of the ASPS Venous Thromboembolism Task Force Report* *Murphy, RX et al. Plast. Reconstr. Surg. 130: 168e, 2012.
12 Stratifying the Risk of Venous Thromboembolism in Otolaryngology Patients with Caprini scores greater than 8 are at an approximately 20-fold increased risk of VTE, and those with scores of 7 to 8 are at an approximately 5- to 10-fold risk when compared with low-risk patients across surgical specialties Shuman, AG et al. Otolaryngology -- Head and Neck Surgery : 719
13 CHEST Consensus Guidelines 2012 Risk Caprini Score *VTE incidence Prophylaxis Very low 0 0.5% Early ambulation Low % IPC Moderate % LMWH, UFH,IPC High % LMWH, UFH + IPC or GS *Estimated baseline risk in the absence of pharmacologic or mechanical prophylaxis Gould, MK et al; CHEST 2012; 141(2)(Suppl):e227S e277s
14 The rate of bleeding complications after pharmacological DVT prophylaxis RCTs in 33,000 patients Complications (%) NA Leonardi MJ, et al. Arch Surg. 2006;141:790-9.
15 Caprini Risk Score Avoids blanket prophylaxis with anticoagulants since those with low scores have a risk of thrombosis that is lower than the bleeding risks with anticoagulation High scores may justify those who might benefit from combined anticoagulant and IPC prophylaxis due to their risk of thrombosis The score can help select patients who would benefit from ongoing prophylaxis after discharge
16 Caprini Scores in Surgical Patients The remarkable association between increasing risk score and clinically-relevant VTE is present over a wide variety of surgical patients. The score has the ability to single out those who are at high risk among surgical populations that have a low global incidence of VTE Justification for extended prophylaxis for those with high scores appears valid since the clinically-relevant VTE rate far exceeds the risk of bleeding Data are available demonstrating that the risk of fatal PE is 0.15% if patients are given a seven day course of unfractionated or low molecular weight heparin prophylaxis*. * Haas S, Wolf H, Kakkar AK, et al. Thrombosis & Haemostasis 2005;94:814-9.
17 Risk Assessment For Bleeding
18 Bleeding events
19 Factors at Admission Associated With Bleeding Risk in Medical Patients The IMPROVE investigators: CHEST 2011;139 (1): 69-79
20 Factors at Admission Associated With Bleeding Risk in Medical Patients The IMPROVE investigators: CHEST 2011;139 (1): 69-79
21 Venous Thromboembolism Following Hospital Discharge
22 Preventing VTE After Discharge The current practice is to administer VTE prophylaxis during hospitalization Upon discharge, it is assumed that the risk of VTE abates, and consequently, prophylaxis is discontinued In reality, the risk persists in patients with ongoing risk factors Remember the efficacy of anticoagulant prophylaxis in clinical trials was based on 5-7 days of prophylaxis Therefore, consider extending prophylaxis after hospitalization in selected patients (Score>4) 22
23 Is Duration of VTE Prophylaxis Analogous to Duration of a Course of Antibiotics? If a patient who is on an antibiotic is admitted to the hospital, and by day 3 is ready to be discharged, would you stop the antibiotic at that point? Of course not the patient should remain on the antibiotic for the duration of a course, 7 to 10 days Or would you see a patient with pneumonia in the ED and wait until the next morning when he/she is on the hospital floor before starting antibiotics? You should think about VTE prophylaxis much the same way
24 Is Duration of VTE Prophylaxis Analogous to Duration of a Course of Antibiotics? Indication Average LOS, d Duration of Prophylaxis Acute medical illness d Abdominal surgery d Hip replacement d or 3 wk Knee replacement d Antibiotic Organism Process Components: 1. Failure to give the antibiotic 2. Resistance of the organism 3. Initial timing of the antibiotic 4. Duration of treatment
25 Time course and clinical presentation of postoperative VTE in RIETE Cumulative incidence % PE Distal DVT Proximal DVT 77% 55% of VTEs were diagnosed after prophylaxis was discontinued Days 24 hours 48 hours 7 days 15 days 30 days 60 days Clinically overt PE 22 (2.8%) 41 (5.2%) 149 (19%) 376 (48%) 608 (77%) 787 Distal DVT 2 (1.1%) 5 (2.78%) 34 (19%) 98 (54%) 145 (80%) 182 Proximal DVT 9 (1.4%) 21 (3.3%) 91 (14%) 248 (39%) 432 (68%) 633 Arcelus JI, et al. Thromb Haemost. 2008;99:
26 Duration of prophylaxis use vs cumulative incidence of VTE following THA and TKA Patients usually discharged from hospital on day 4 5 By PO day seven, 25% were not receiving prophylaxis Patients receiving prophylaxis (%) Cumulative VTE incidence All prophylaxis Days after surgery Cumulative VTE incidence (number of events) Warwick D, et al. J Bone Joint Surg. 2007;89B:
27 Million Women Study Prospective cohort study involving 947,454 woman followed for 6 years Surgery was done in 239,614 patients with 5419 VTE events including 270 VTE related deaths Compared with not having surgery, women were 70 times more likely to be admitted with venous thromboembolism in the first six weeks after an inpatient operation and 10 times more likely after a day case operation. The risks were lower but still substantially increased 7-12 weeks after surgery. Sweetland S, et al, BMJ 2009;339:b4583
28 Rates Of Venous Thromboembolism Occurrence in Medically-ill Patients (Data from Premier insured database) Spyropoulos, AC et al:thromb Haemost 2009; 102:
29
30 Use of a Retrievable Vena Cava Filter with Low- intensity Anticoagulation for Prevention of Pulmonary Embolism in Patients with Cancer: An Observational Study in 106 Cases PE recurred in three of 58 patients (5.2%). None of the 48 patients with DVT alone developed PE or had recurrent DVT The filter was removed in 14 patients (13.2%) 16 complications occurred in seven patients: one migration (0.9%); four cases of vena cava thrombosis (3.7%), three of which were associated with recurrent PE (2.8%); one filter fracture (0.9%); and one IVC penetration (0.9%). Filter tilting greater than 15 occurred in six patients (5.7%) and was associated with other complications in five (4.7%) Damascelli, B et al: J Vasc Interv Radiol 2011; 22:
31 Use of a Retrievable Vena Cava Filter with Low- intensity Anticoagulation for Prevention of Pulmonary Embolism in Patients with Cancer: An Observational Study in 106 Cases Indications for retrieval of the filter were documented resolution of the DVT or no evidence over time of recurrence of PE in patients without DVT at the time of enrollment Low-intensity warfarin keeping the INR between 1.5 and 2.0 was used during the study LMWH bridging was used for filter placement and removal Although these were cancer patients the study shows the range and severity of complications associated with filter placement and removal The use of full-dose LMWH anticoagulation long-term is an alternative that needs to be compared to this strategy before recommending this approach in the cancer patient. Damascelli, B et al: J Vasc Interv Radiol 2011; 22:
32 Antiembolism Stockings: Myth Vs. Reality
33 Antiembolism Stockings Ineffective Post Stroke in Preventing DVT Immobile acute stroke patients (N=2518) Standard care, with or without thigh-high graduated compression stockings (GCS) Duplex ultrasound of both legs at 7-10 days and days after enrollment Proximal DVT rates were not significantly different between groups (10.0% and 10.5% with and without GCS, respectively) Skin breaks, ulcers, and blisters were more common with GCS vs without GCS (5% vs 1%, respectively) Conclusion: Do not use in medical patients The CLOTS Trials Collaboration. Lancet. 2009;373:
34 Thigh-Length Versus Below-Knee Antiembolism Stockings for Deep Venous Thrombosis Prophylaxis After Stroke--A Randomized Trial (CLOTS 2) The CLOTS (Clots in Legs Or stockings after Stroke) Trial Collaboration* This study involved 1552 immobile stroke patients who were randomized to receive either thigh-length or belowknee stockings during hospitalization. Proximal DVT occurred in 98 patients (6.3%) who received thigh-length stockings and 138 (8.8%) who received below-knee stockings; P= 0.008, an odds reduction of 31% (CI, 9% to 47%). Skin breaks occurred in 61 patients who received thighlength stockings (3.9%) and 45 (2.9%) who received below-knee stockings. Ann Intern Med. 2010;153:
35 80mmHg 60mmHg 40mmHg 20mmHg
36 Antiembolism Stockings Edema Skin lesion Ulceration
37 Conclusions Remember the many faces of VTE Perform a complete risk assessment (H&P) for both thrombosis and bleeding Extend prophylaxis for the period of time that the patient is at risk Avoid the use of antiembolism stockings as a sole thromboprophylaxis method Be extremely selective in the use of vena cava filters
38
39 Which One of the Following Statements is Not True? a) The caprini score represents the total of weighted risk factors. b) A caprini score of >8 is associated with a 20 fold incidence of VTE compared to those with a low-risk score. c) The score has been validated in a variety of surgical groups. d) The score is too complex for use without an electronic medical record.
40 Which One of the Following Statements is Not True? A) Most VTE events do not occur during hospitalization. B) Seventy-seven percent of VTE events occur following hospital discharge. C) The mean time to develop VTE in medical patients is day 74. D) When screening tests for VTE are done they disprove the theory that most events occur after discharge.
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery Position Statement There is currently insufficient data for the (AOFAS) to recommend for or against routine VTED prophylaxis for
Venous Thromboembolic Treatment Guidelines
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare
Update on Venous Thromboembolism Prophylaxis Disclosure No conflicts of interest to declare Learning Objectives After completion of this presentation, participants should be able to: Define venous thromboembolism,
Trust Guideline for Thromboprophylaxis in Trauma and Orthopaedic Inpatients
A clinical guideline recommended for use In: By: For: Key words: Department of Orthopaedics, NNUHT Medical staff Trauma & Orthopaedic Inpatients Deep vein thrombosis, Thromboprophylaxis, Orthopaedic Surgery
DATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital
Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Jonathan Sykes MD, CMIO Jacalyn Liebowitz RN, MBA,NEA-BCFACHE VP Care Continuum Allegiance Health - Jackson, MI DISCLAIMER:
Thrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit
Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014 Thromboembolism epidemiology 5 million DVT s 900,000 PE s 290,000 fatalities Heit J. Blood. 2005;106:910. 10 VTE events Since this talk began DVT
New Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
Overview of the TJC/CMS VTE Core Measures
Overview of the TJC/CMS VTE Core Measures CMS Specification Manual 4.2 January 1, 2013 June 30, 2013 Victoria Agramonte, RN, MSN Project Manager, IPRO VTE Regional Learning Sessions NYS Partnership for
What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?
Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC
To Bridge or Not to Bridge Periop Anticoagulation Management Don Weinshenker, MD Ambulatory Care Denver VAMC Financial Disclosure Information Nothing to report Periop AC Management Chronically anti-coagulated
CDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
Confirmed Deep Vein Thrombosis (DVT)
Confirmed Deep Vein Thrombosis (DVT) Information for patients What is deep vein thrombosis? Blood clotting provides us with essential protection against severe loss of blood from an injury to a vein or
Gruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
Venous thromboembolism: reducing the risk. Quick reference guide. Issue date: January 2010
Issue date: January 2010 Venous thromboembolism: reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital This guideline
Investor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
Paul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, 1998-1999. A. Objective
A comparison of six months of anticoagulation with extended anticoagulation for a first episode of venous thromboembolism in patients with thrombophilia Paul G. Lee A. Objective a. To evaluate the risk
Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip
Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre
Anticoagulation at the end of life. Rhona Maclean [email protected]
Anticoagulation at the end of life Rhona Maclean [email protected] Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
Pulmonary Embolism Treatment Update
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto
News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval
DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION
DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION Venous thromboembolism is the most common complication after total hip and total knee arthroplasty. In recent times members of the Australian Orthopaedic
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
Guidelines for diagnosis and management of acute pulmonary embolism
Guidelines for diagnosis and management of acute pulmonary embolism By Dr. Ahmed Zaghloul M.D. Anesthesia & Critical Care 2014 Predisposing factors for VTE Predisposing factor Strong predisposing factors
2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
Committee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY
1 UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY ABSTRACT Ph.D student DR. TRUŞCĂ PAUL TIBERIU SCIENTIFIC COORDONATOR PROF. DR.VALENTIN
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
Central Venous Catheters and Upper Extremity DVT: Update, Diagnosis and Management
Central Venous Catheters and Upper Extremity DVT: Update, Diagnosis and Management David Hahn, MD Interventional Radiology NorthShore University HealthSystem Objectives Discuss the epidemiology and clinical
Prevention of Venous Thromboembolism
Policy Directive Prevention of Venous Thromboembolism Document Number PD2010_077 Publication date 22-Dec-2010 Functional Sub group Corporate Administration - Governance Clinical/ Patient Services - Surgical
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
Antithrombotic Therapy for VTE Disease
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
Antithrombotic Therapy for VTE Disease
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
ANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE
ANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE Jamie N. Nadler, M.D. Assistant Professor of Medicine State University of New York at Buffalo Department of medicine Division
Anti-Coagulation Therapies: A Review of Best Practices for Managing Risk
Volume 20 No. 1 Spring 2012 Anti-Coagulation Therapies: A Review of Best Practices for Managing Risk Dear Colleague: This first newsletter of 2012 deals with an important aspect of patient care the monitoring
Randomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 General Principles: There is compelling data in the medical literature to support
How To Take Xarelto
A patient's guide Your clinic's contact details are: Name: Contact number: Contents 2 Why have I been prescribed Xarelto? 2 What is Xarelto? 3 How do I take Xarelto? 3 What should I do if I miss a dose
Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
CLINICAL PRACTICE GUIDELINE: MOBILITY WITH A DEEP VEIN THROMBOSIS (DVT) Page 1 of 10
Page 1 of 10 1.0 FOCUS: Mobilization with a Deep Vein Thrombosis (DVT). The purpose of this clinical practice guideline (CPG) is to ensure that new knowledge is integrated across Fraser Health and to standardize
Clinical practice guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to
Clinical practice guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to Australian hospitals DRAFT FOR PUBLIC CONSULTATION 2009 Commonwealth
3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery
XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)
Prior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
Reducing Adverse Drug Events With Anti Coagulation Clinics. McFarland Clinic. McFarland Protime Clinic 09/05/12
Reducing Adverse Drug Events With Anti Coagulation Clinics Dr. Donald Skinner, MD McFarland Clinic 182 Physicians (149 Shareholders) 40 Mid Level Providers 13 Administrators/Executive Directors 1,200 Support
Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
Preventing Blood Clots in Adult Patients. Information For Patients
Preventing Blood Clots in Adult Patients Information For Patients 1 This leaflet will give you information on how to reduce the risk of developing blood clots during and after your stay in hospital. If
Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
Backgrounder. Current anticoagulant therapies
Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events
Breadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014
CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 e 55 0495 2 Emergency Department (ED)- 1 Emergency Department Throughput Median time from
Your Guide to Preventing and Treating Blood Clots
Your Guide to Preventing and Treating Blood Clots U.S. Department of Health and Human Services Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 AHRQ Pub. No. 09 0067 C May
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
Taole Mokoena DPhil FRCS Department of Surgery University of Pretoria
ETHICAL DILEMMA S OF VENOUS THROMBO-EMBOLISM IN FINANCIAL RESOURCE STARVED ENVIRONMENT Taole Mokoena DPhil FRCS Department of Surgery University of Pretoria The Magnitude of Venous Thrombo-Embolism Hospitalization
National Guidance and New Protocols
National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 Autumn dawn Restless geese take flight
Venous and Lymphatic Disorders
Venous and Lymphatic Disorders. ก. Venous and Lymphatic Disorders Varicose Veins Deep Vein Thrombosis (DVT) Lymphedema What Is Varicose Veins? Latin: Varicose = Varix = twisted Abnormal venous dilatation
rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC
rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications
Time of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
National Guidance and New Protocols
National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 DVT patient pathway Assessment Diagnosis
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven
Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked
New Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
ABSTRACT The American Physical Therapy Association (APTA), in conjunction with the
The Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed with Venous Thromboembolism An Evidence Based Clinical Practice Guideline Guideline Development Group: Ellen Hillegass,
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
Review Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty
Thrombosis Volume 2013, Article ID 762310, 5 pages http://dx.doi.org/10.1155/2013/762310 Review Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and
4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
(a) New Oral Anticoagulants & (b) Neuropathic Pain
Evidence Updates: (a) New Oral Anticoagulants & (b) Neuropathic Pain Brendalynn Ens, RN, MN, CCN(c) CADTH-Saskatchewan Gaetanne Murphy, BSc Pharm CADTH-Edmonton CADTH s Programs HTA CDR Health Technology
How To Manage An Anticoagulant
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
Advanced Issues in Peri-Operative VTE Prevention
Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-
